Charles River Laboratories International reaffirmed its 2026 earnings per share guidance of $10.80 to $11.30 during a recent earnings call [1].
This guidance comes as the company undergoes a leadership transition and attempts to stabilize profit margins amid a shifting strategic framework. The ability to meet these targets depends on the successful completion of planned divestitures and the efficacy of new cost-saving initiatives.
For the first quarter of 2026, the company reported revenue of $995.8 million [4]. The adjusted earnings per share for the same period were $2.06 [3]. While these figures provide a baseline for the year, the company faced a contraction in margins during the first quarter [5].
Despite the recent dip in margins, management is targeting a margin expansion of approximately 120 to 150 basis points [2]. The company said this growth will be driven by a refreshed strategic framework, and the closing of divestitures. These moves are intended to streamline operations and reduce overhead.
Birgit Girshick assumed the role of chief executive officer this week [6]. Her appointment coincides with the company's push to meet its long-term financial goals through operational efficiency.
The company is focusing on cost-saving measures to offset the flat growth experienced in certain sectors. By shedding non-core assets through divestitures, the firm aims to improve its overall profitability profile by the end of the 2026 fiscal year [1].
“Charles River Laboratories reaffirmed its 2026 EPS guidance of $10.80 to $11.30.”
The reaffirmation of 2026 targets suggests management believes the current margin contraction is a temporary byproduct of restructuring rather than a systemic decline. By prioritizing divestitures and cost-cutting under new leadership, the company is attempting to pivot from a growth-at-all-costs model to one focused on lean operational efficiency and margin recovery.
